Mucormycosis of the head and neck

Current Infectious Disease Reports

Volumn 13, Issue 2, 2011, Pages 123-131

  Dan, Michael ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Amphotericin B deoxycholate; Amphotericin B lipid formulations; Azoles; Deferoxamine; Diabetes mellitus; Echinocandins; Hematopoietic stem cell transplant recipients; Immunocompromising conditions; Iron overload; Mucorales; Mucormycosis; Posaconazole; Rhino orbitocerebral mucormycosis; Solid organ transplant recipients

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; DEFERASIROX; MICAFUNGIN; POLYENE; POSACONAZOLE;

CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; ENDOSCOPY; FUNGUS CULTURE; HEAD AND NECK INFECTION; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; INFECTION CONTROL; MUCORMYCOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID ANALYSIS; PATHOGENESIS; REVIEW; TISSUE NECROSIS; TREATMENT PLANNING;

EID: 79955948830     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-010-0162-8     Document Type: Review

References (60)

1. Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-569. (Pubitemid 40995116)
2. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653. (Pubitemid 41170352)
3. Antachopoulos C, Gea-Banacloche JC, Walsh TJ: Zygomycosis (Mucormycosis). In: Hospenthal DR, Rinaldi MG, eds. Diagnosis and Treatment of Human Mycoses. Totowa, NJ: Humana Press; 2008:227-24.
4. Kontoyianis DP, Vartivarian S, Anaissie EJ, et al.: Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis 1994;18:925-928. (Pubitemid 24171338)
5. Ribes JA, Vanover-Sams CL, Baker DJ: Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.
6. Rees JR, Pinner RW, Hajjeh RA, et al.: The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: Results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27:1138-1147.
7. Kontoyiannis DP, Marr KA, Park BJ, et al.: Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-1100. In a national prospective surveillance study in 23 US transplant centers of invasive fungal infections occurring between 2001 and 2006 in hematopoietic stem cell transplant recipients, the cumulative incidence of mucormycosis was third after that for aspergillosis and candidiasis.
8. Pappas PG, Alexander BD, Andes DR, et al.: Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111. A prospective study conducted in 15 US organ transplant recipient centers identified invasive fungal infections occurring between 2001 and 2006. Mucormycosis was diagnosed in 2% of the patients and was common among heart and lung transplants (3% each).
9. Bitar D, Van Cauteren D, Lanternier F, et al.: Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009, 15:1395-1401. This study analyzed hospital records to provide a population-based estimate of mucormycosis incidence and trends over a 10-year period at a national level in France. Data showed an increasing incidence from 0.7 per million in 1997 to 1.2 per million in 2006, particularly in patients with hematologic malignancies or bone marrow transplants.
10. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1360.
11. Oren I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
12. Trifilio S, Singhal S, Williams S, et al.: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-456. (Pubitemid 47288224)
13. Gleissner B, Schilling A, Anagnostopolous I, et al.: Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004; 45:1351-1360. (Pubitemid 38701909)
14. Kontoyiannis DP, Lewis RE: Agents of mucormycosis and entomophthoramycosis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (7th edition). Philadelphia: Churchill Livingstone; 2009, p 3257-3269.
15. Fujii T, Takata N, Katsutani S, Kimura A: Disseminated mucormycosis in an acquired immunodeficiency syndrome (AIDS) patient. Intern Med 2003 42:129-130. (Pubitemid 36267682)
16. Thajeb P, Thajeb T, Dai D: Fatal strokes in patients with rhinoorbito- cerebral mucormycosis and associated vasculopathy. Scand J Infect Dis 2004;36:643-8. (Pubitemid 39294909)
17. Sims CR, Ostrosky-Zeichner L: Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007;38: 90-93. (Pubitemid 44894615)
18. Elinav H, Zimhony O, Cohen MJ, et al.: Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009;15:693-7.
19. Talmi YP, Goldschmied-Reouven A, Bakon M, et al.: Rhinoorbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127:22-31.
20. Shpitzer T, Keller N, Wolf M, et al.: Seasonal variations in rhinocerebral Mucor infection. Ann Otol Rhinol Laryngol. 2005;114:695-8. (Pubitemid 41356105)
21. Spellberg B, Ibrahim AS: Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010; 12:423-429. This article provides a comprehensive review of recent advances in the treatment of mucormycosis.
22. Shoham S, Levitz SM: The immune response to fungal infections. Br J Haematol 2005;129:569-582. (Pubitemid 40825818)
23. Boelaert JR, de Locht M, Van Cutsem J, et al.: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Investig 1993; 91:1979-1986. (Pubitemid 23141469)
24. Ibrahim AS, Gebermariam T, Fu Y, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117:2649-2657. This article reports a study describing the potential role of iron chelation as adjunctive therapy for mucormycosis.
25. Yohai RA, Bullock JD, Aziz AA, et al.: Survival factors in rhinoorbital- cerebral mucormycosis. Surv Ophthalmol 1994; 39:3-22. (Pubitemid 24243492)
26. Skiada A, Vrana L, Polychronopoulou H, et al.: Disseminated zygomycosis with involvement of the central nervous system. Clin Microbiol Infect 2009 Oct;15 Suppl 5:46-9.
27. Hopkins RJ, Rothman M, Fiore A, Goldblum SE: Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994, 19:1133-1137. (Pubitemid 24380030)
28. Harril WC, Stewart MG, Lee AG, et al.: Chronic rhinocerebral mucormycosis. Laryngoscope 1996;106:1292-7. (Pubitemid 26330865)
29. Paterson PJ, Marshall SR, Shaw B, et al.: Fatal invasive cerebral Absidia corymbifera infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26: 701-703.
30. Nenoff P, Kellerman S, Schober R, et al.: Rhinocerebral zygomycosis following bone marrow transplantation in chronic myeologenous leukaemia. Report of a case and review of the literature. Mycoses 1998; 41: 365-372. (Pubitemid 29039388)
31. Olalla I, Ortin M, Hermida G, et al.: Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis. Bone Marrow Transplant 1996;18: 1183-1184. (Pubitemid 27026280)
32. Macdonell RA, Donnan GA, Kalnins RM, et al.: Otocerebral mucormycosis: A case report. Clin Exp Neurol 1987;23:225-2232.
33. Yun MW, Lui CC, Chen WJ: Facial paralysis secondary to tympanic mucormycosis: Case report. Am J Otol 1994;15:413-4. (Pubitemid 24164955)
34. Tuzcu A, Bahceci M, Celen M, et al.: Necrotizing (malignant) otitis externa: An unusual localization of mucormycosis. Indian J Med Microbiol 2006; 24: 289-91. (Pubitemid 46033983)
35. Arnáiz-García ME, Alonso-Peña D, González-Vela Mdel C, et al.: Cutaneous mucormycosis: report of five cases and review of the literature. J Plast Reconstr Aesthet Surg 2009;62:e434-41.
36. Numa WA, Jr., Foster PK, Wachholz J, et al.: Cutaneous mucormycosis of the head and neck with parotid gland involvement: first report of a case. Ear Nose Throat J 2004;83:282-8. (Pubitemid 38534057)
37. Chandu A, MacIsaac RJ, MacGregor DP, et al.: A case of mucormycosis limited to the parotid gland. Head Neck 2005;27:1108-11. (Pubitemid 41705590)
38. Goyal A, Tyagi I, Syal R, et al.: Apophysomyces elegans causing acute otogenic cervicofacial zygomycosis involving salivary glands. Med Mycol 2007;45:457-461. (Pubitemid 47190132)
39. Chuang Y-C, Kuo Y-L, Lui C-C, et al.: Facial nerve paralysis resulting from parotid involvement with mucormycosis. Infect Dis Clin Pract. 2000;9:36-8. (Pubitemid 30030632)
40. Brown OE, Finn R: Mucormycosis of the mandible. J Oral Maxillofac Surg 1986;44:132-136. (Pubitemid 16053347)
41. Gussen R, Canalis RF: Mucormycosis of the temporal bone. Ann Otol Rhinol Laryngol 1982;91(1 Pt 1):27-32. (Pubitemid 12183959)
42. Vessely MB, Zitsch RP 3rd, Estrem SA, Renner G: Atypical presentations of mucormycosis in the head and neck. Otolaryngol Head Neck Surg 1996;115:573-577. (Pubitemid 26424450)
43. Bahna MS, Ward PH, Konrad HR: Nasopharyngeal mucormycotic osteitis: a new syndrome characterized by initial presentation of multiple cranial nerve palsies. Otolaryngol Head Neck Surg 1980;88:146-513.
44. Rickerts V, Mousset S, Lambrecht E, et al.: Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007;44:1078-1083. (Pubitemid 46580276)
45. Dannaoui E, Schwarz P, Slany M, et al.: Molecular detection and identification of zygomycetes species from paraffin embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010;48:2043-2046. The authors report a promising study on the use of PCR in the rapid diagnosis of mucormycosis from paraffin embedded tissue.
46. Chamilos G, Lewis RE, Kontoyiannis DP: Delaying amphotericin B-based front-line therapy significantly increases mortality in hematologic malignancy patients with zygomycosis. Clin Infect Dis 2008;47:503-509.
47. Petrikkos GL: Lipid formulations of amphotericin B as first-line treatment of Zygomycosis. Clin Microbiol Infect 2009;15 (Suppl. 5): 87-92.
48. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE, Jr.: Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003;47:3343-3344.
49. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005;40(Suppl 6):S401-S408.
50. Larkin JA, Montero JA: Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20: 201-206. (Pubitemid 36511530)
51. Walsh TJ, Hiemenz JW, Seibel NL, et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26: 1383-1396. (Pubitemid 28270170)
52. Sun H-Y, Forres G, Gupta KL, et al.: Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010;90:85-92
53. Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-371. This retrospective study reports on the superior results of the combination of polyene and echinocandin in patients with mucormycosis.
54. Spellberg B, Walsh TJ, Kontoyiannis DP, et al.: Recent Advances in the Management of Mucormycosis: From Bench to Bedside. Clin Infect Dis 2009;48: 1743-1751.
55. van Burik JA, Hare RS, Solomon HF, et al: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-e65.
56. Greenberg RN, Mullane K, van Burik JA, et al: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-133. (Pubitemid 43042912)
57. Ibrahim AS, Bowman JC, Avanessian V, et al.: Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005;49:721-727. (Pubitemid 40175685)
58. Ibrahim AS, Gebremariam T, Fu Y, et al.: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008;52:1556-1558. (Pubitemid 351522035)
59. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al.: Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005;191:1180-118.
60. Reed C, Ibrahim A, Edwards JE, Jr., et al.: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006;50:3968-3969. (Pubitemid 44684931)